Gottlieb Outlines Opioid Fight

News
Article

FDA’s new commissioner asks staff for suggestions for fighting the opioid crisis.

On May 23, 2017, FDA Commissioner Scott Gottlieb, MD, posted a blog post detailing his plans to fight the opioid addiction crisis, including a new steering committee. The commissioner also asked his staff for their input on how to combat this important health issue.

One of the first parts of the agency’s plan is the creation of the Opioid Policy Steering Committee, which will consist of FDA senior leaders. The committee is charged with reviewing the need for education for healthcare professions, the possible tailoring of the number of dosages, and the agency’s framework for assessing opioid abuse.

“Working together, we need to do all we can to get ahead of this crisis. That’s why we’ll also be soliciting public input, through various forums, on what additional steps FDA should consider. I look forward to working closely with my FDA colleagues as we quickly move forward, capitalizing on good work that has already been done, and expanding those efforts in novel directions. I will keep you updated on our work as we continue to confront this epidemic,” Gottlieb stated in the blog post.

Source: FDA

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.